1. Summarize the biology of t(11;14) myeloma
  2. Explain the natural history and expected clinical outcome for patients with t(11;14) myeloma
  3. Analyze the role of BCL2 inhibition in treating t(11;14) myeloma
  4. Examine the current clinical data for the use of venetoclax in myeloma


Zoom link: https://uwmadison.zoom.us/s/95367945796?pwd=RnQwdTVSWTlBQXc2a1NseTBDODlqUT09

Session date: 
03/30/2022 - 8:00am to 9:00am CDT
Clinical Science Center, G5/119
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™

Please login or register to take this course.
Discloser List CME Internal Report
Dr. Jonathan Kaufman